Posted inComunicati
Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE BASEL, Switzerland and LINCOLNSHIRE, Ill., Aug. 11, 2026 /PRNewswire/ --…









